Latest HER2/neu Stories

A team of researchers at Case Western Reserve University School of Medicine, led by Dr. Mark W. Jackson, have developed a novel method to identify genes that, when overexpressed, make normal cells behave like cancer cells. Using this method, the Jackson laboratory has identified a new oncogene, which is a gene that contributes to the development of cancer, named FAM83B. "We made our discovery in a model of breast cancer," said Mark W. Jackson, Ph.D., Assistant Professor, Department of...

EAST HANOVER, N.J., July 20, 2012 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved Afinitor(®) (everolimus) tablets for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ breast cancer) in combination with exemestane after failure of treatment with letrozole or anastrozole(2). To view the multimedia assets associated with this release, please click:...

ATLANTA, June 28, 2012 /PRNewswire-USNewswire/ -- From today's Supreme Court ruling that upholds the Affordable Care Act (ACA) to the FDA's approval of the first new obesity drug in 13 years, June has been a hot month for major news impacting the U.S. biotechnology sector. (Logo: http://photos.prnewswire.com/prnh/20120628/DC32901LOGO) Biopharmaceutical drugmakers have held their collective breath wondering what would happen with health care reform and many hesitated to commit...

Breakthrough Study Led by Rethink Breast Cancer Board Member TORONTO, June 4, 2012 /CNW/ - Today Rethink Breast Cancer (Rethink) celebrates new study results that bring hope to the more than 5,000 Canadian women living with HER2-positive breast cancer. The study, led by Dr. Sunil Verma, Medical Oncologist at Sunnybrook Odette Cancer Centre and Rethink Board Member, showed promising results for a new treatment for patients living with HER2-positive metastatic breast cancer...

Researchers and doctors at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research have discovered a potential explanation for why breast cancer is not experienced the same way with African American and Caucasian patients. Chicago, IL (PRWEB) June 02, 2012 Researchers and doctors at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research have discovered a potential explanation for why breast cancer is not experienced the same way with...

CHICAGO, June 2, 2012 /PRNewswire/ -- -- TLE3 Biomarker Over-expressed in HER2-positive, Hormone Receptor-positive, and Triple-negative Breast Cancers -- -- EGFR status May Facilitate Therapeutic Decision-making in Head and Neck Cancer -- Caris Life Sciences announced today the utility of the company's Caris Target Now(TM) evidence-based molecular profiling service in the characterization of breast and head and neck cancers. These data were presented today at the...

Multiple research projects – including a 2006 study conducted at the University of North Carolina at Chapel Hill – have used DNA microarray analysis to identify several breast cancer subtypes, including luminal A, luminal B, basal-like and HER2-enriched. Simple tests are being developed to help doctors identify these subtypes and to treat their patients in a more biologically-based way. In turn, these tests have made several studies possible that indicate that basal-like, or triple...

Novel adjuvant therapy shows promise for women with a history of breast cancer in Phase II clinical trial A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from a clinical trial led by researchers at The University of Texas MD Anderson Cancer Center. The findings, released today, will be presented on...

Targeted therapies have been studied for years, but recent laboratory research is providing robust clues about drugs that might work better in combination, particularly in treating cancers that have become resistant to therapy. That kind of information is behind a novel clinical trial at Georgetown Lombardi Comprehensive Cancer Center that combines cetuximab and lapatinib. Findings from this phase I study will be presented at the American Society of Clinical Oncology annual meeting in...

MOUNTAIN VIEW, Calif., May 16, 2012 /PRNewswire/ -- Although there are approximately 27 drugs on the market indicated for the treatment of breast cancer, there is currently an unmet need to treat patients. Consequently, there are abounding opportunities for pharmaceutical manufacturers, as breast cancer is the second most common cancer among women. There are currently 55 breast cancer therapeutic drugs in the developmental phase in the U.S., with additional drugs expected...